ClinicalTrials.gg
CompletedNCT05044507BQ5Updated Mar 19, 2024

The Efficacy of a Frequency-tuned Electromagnetic Field Treatment in Facilitating the Recovery of Subacute Ischemic Stroke Patients - a Pivotal Study (THE "EMAGINE" STUDY)

An interventional study of BQ 2.0 and BQ 2.0 in Ischemic Stroke, sponsored by BrainQ Technologies Ltd.. Completed at 15 sites in United States. Open to participants aged 22 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-03-19.

Sponsored by BrainQ Technologies Ltd. · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was Nov 2023, 3 years ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
22 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 480 studies in Ischemic Stroke with a site in United States — 120 open to participants now, 145 under way, 13 of them phase 3. Ischemic Stroke · United States.

Enrollment
146th of 364
100 · median 65
Started
2021
with 36 others
No phase
183 of 480
51 open now
Registered
309th of 480
by date

Among the 480 studies in Ischemic Stroke with a site in United States, this one is the 146th largest by enrollment of the 364 interventional ones that give a count, is one of 37 that started in 2021, is one of 183 with no phase, and was the 309th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

120 of the 480 studies in Ischemic Stroke with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 22 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 480 studies in Ischemic Stroke with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter study that will be conducted at approximately 20 centers. BQ 2.0 is a wearable medical device that produces and delivers non-invasive, extremely-low-intensity and low-frequency, frequency-tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery.

In this study, BQ 2.0 is intended to reduce disability in adult patients with subacute ischemic stroke, with a moderate to severe disability which includes an upper extremity motor impairment.

BQ 2.0 will be used for 9 weeks in conjunction with physical and occupational therapy (PT/OT) and periodic supervision (either remote or in person) of a trained site study team member. Treatments may be administered in multiple settings (e.g. acute care hospital (ACH) or inpatient rehabilitation facilities (IRF), Skilled Nursing Facility (SNF), home or other outpatient setup).

The study will enroll up to 150 adult subjects who will be randomly assigned (1:1 allocation ratio) to either active or sham study intervention using BQ 2.0.

Read the detailed description

The study intervention will be initiated 4-21 days after the index stroke event and will consist of a total of 45 sessions over a period of 9 weeks (5 treatments per week). Each session will last 60 minutes during which 40 net minutes of active or sham study intervention using BQ 2.0 will be administered. Each study group will receive a standardized, pre-defined and evidence-based physical and occupational therapy regimen concurrent with the study intervention.

Screening phase:

Prospective subjects, who are 3 to 21 days post-stroke, will be consented to participate in the study at either:

  1. a participating initial acute care hospital (ACH), prior to anticipated transfer to a participating IRF, SNF, Outpatient or home setting or
  2. at a participating IRF, SNF, outpatient or home setting

Consented subjects, who are 4 to 21 days post-stroke will be screened for eligibility to participate in the treatment phase of the study.

Eligible subjects will be randomly assigned, at a 1:1 allocation ratio, to either the active or sham study intervention groups.

Treatment and follow-up Randomized patients will proceed to the treatment phase of the study. Active or sham study intervention sessions using BQ 2.0 (active or sham therapy, respectively) will be conducted 5 times a week, starting 4-21 days after stroke onset and no later than 2 days after randomization. Each session will last 60 minutes, with active or sham field being turned on for up to 40 minutes. The only difference between the BQ 2.0 active stimulation and sham therapy is that the sham device does not generate electromagnetic fields during treatment. Subjects in both the active intervention group (BQ 2.0 group) and sham group will be asked to perform device guided physical and occupational therapy activities during each session. Participation in the study will not replace any of usual care patient should recieve.

Subjects will undergo a detailed interim outcome assessment on the 20th (±4) day of treatment and a detailed primary endpoint outcome assessment on the 90th (±15) day after the onset of the index stroke. In addition, a focused, long-term outcome assessment on the 180th (±15) day after the onset of the index stroke will be performed.

03

Conditions studied

  • Ischemic Stroke

Browse trials for

Keywords

  • subacute
04

Who can participate

Ages eligible
22 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. mRS score of 3 or 4.
  2. FMA-UE score between 10-45 (inclusive) of impaired limb.
  3. Age 22 to 85 years of age (inclusive).
  4. Diagnosed with an ischemic stroke, confirmed by CT or MRI imaging.
  5. 4 to 21 days from stroke onset (or last known well).
  6. Pre-stroke mRS of 0 or 1.
  7. Able to sit with the device for 40 consecutive minutes.
  8. Can follow a 3-step command, such as "take the paper, fold it in half, and return it to me".
  9. Willingness to participate in occupational/physical therapy activities during study intervention sessions.
  10. Availability of a relative or other caregiver able to assist during PT/OT treatment delivered via video call sessions during the study.
  11. If female, not pregnant (as confirmed by a urine or a blood test, or as determined by an official medical document) or breastfeeding and with no ability to become pregnant or on an acceptable method of during the study
  12. signed by subject (if competent) or legally authorized representative.

Exclusion criteria

Exclusion Criteria:

  1. Severe neglect impairment (NIHSS item 11 score = 2) or neglect that is severe enough to interfere with reasonable performance of study procedures. assessments or treatments.
  2. Implanted active electronic or passive MR-incompatible devices.
  3. Previous ischemic or hemorrhagic stroke within the 2 weeks before the index stroke.
  4. Pre-existing neurological condition (eg, Alzheimer's disease, Parkinson's disease, multiple sclerosis, traumatic brain injury, spinal cord injury) or physical limitation that would interfere significantly with the subject's participation in the study and/or confound neurological or functional evaluation.
  5. Active epilepsy or currently taking anti-epileptic medication (indicated for the treatment of a seizure disorder), or seizure in the last 5 years.
  6. Significant visual disturbances that cannot be corrected and that would interfere significantly with the subject's participation in the study and/or confound neurological or functional evaluation.
  7. Unstable serious illness/condition (eg, active cancer, severe heart failure, active psychiatric condition) or of less than 6 12 months.
  8. A known severe allergic reaction to acrylic-based adhesives.
  9. Ongoing alcohol abuse and/or illicit drug use.
  10. Participation in another trial that would conflict with the current study or clinical endpoint interference may occur.
  11. Employee of the Sponsor.
  12. Prisoner.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
100 participants (actual)

Study arms

  • Sham comparator
    BQ 2.0 sham stimulation group

    45 sessions over a period of 9 weeks (5 treatments per week) of sham study intervention with BQ 2.0 including a standardized, pre-defined and evidence-based physical and occupational therapy regimen concurrent with the study intervention.

    Device: BQ 2.0

  • Active comparator
    BQ 2.0 active stimulation group

    45 sessions over a period of 9 weeks (5 treatments per week) of active study intervention with BQ 2.0 including a standardized, pre-defined and evidence-based physical and occupational therapy regimen concurrent with the study intervention.

    Device: BQ 2.0

Interventions

  • DeviceBQ 2.0

    frequency and intensity parameters will be set to zero so that no stimulation is delivered

    Also known as: BQ 2.0 sham stimulation group

  • DeviceBQ 2.0

    The BQ 2.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; up to 1 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery

    Also known as: BQ 2.0 active stimulation group

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Modified Rankin Scale

    Mean change in mRS score from baseline (post-stroke day 4-21) to 90 days post stroke (90 ±15 days post-stroke)

    Time frame: change from baseline (4-21 days post stroke) to 90 days post stroke. mRS will be assessed at 90 Day FU visit

Secondary outcomes

  1. Change from Baseline in Fugl-Meyer Assessment for Upper Extremity (upper limb function)

    Lead secondary endpoint: Fugl-Meyer Assessment for Upper Extremity (upper limb function) - to show that the BQ therapy is effective in reducing upper limb impairment, and improving upper limb functionality

    Time frame: change from baseline (4-21 days post stroke) to 90 days post stroke. FMA-EU will be assessed at 90 Day FU visit

  2. Change from Baseline in Box and Block Test (fine hand function)

    Secondary Endpoint: to show that the BQ therapy is effective in reducing upper limb impairment, and improving upper limb functionality

    Time frame: change from baseline (4-21 days post stroke) to 90 days post stroke (will be assessed at 90 Day FU visit)

  3. Change from Baseline in 10 Meter Walk Test (gait speed)

    Secondary Endpoint: To show the BQ therapy is effective in reducing lower limb imperement

    Time frame: change from baseline (4-21 days post stroke) to 90 days post stroke. (will be assessed at 90 Day FU visit )

  4. Change from baseline in Stroke Impact Scale Hand Domain (patient-reported hand function)

    Secondary Endpoint: to show that the BQ therapy is effective in reducing upper limb impairment, and improving upper limb functionality

    Time frame: change from baseline (4-21 days post stroke) to 90 days post stroke (will be assessed at 90 Day FU visit )

  5. Change from baseline in Stroke Impact Scale 16 (patient-reported physical functional limitation)

    Secondary Endpoint: to show that the BQ therapy is effective in reducing upper limb impairment, and improving upper limb functionality

    Time frame: change from baseline (4-21 days post stroke) to 90 days post stroke (will be assessed on 90 Day FU visit )

  6. Change from baseline in 5-level EQ-5D (health-related quality of life)

    Secondary Endpoint: To show that the BQ therapy is effective in improving health-related quality of life (HRQoL)

    Time frame: Change from baseline (4-21 days post-stroke) to 90 days post-stroke (will be assessed on 90 Day FU visit )

Other outcomes

  1. Serious procedure or device related adverse events & device deficiencies

    Safety: To characterize the safety profile of the BQ therapy and to show that the BQ 2.0 performs reliably.

    Time frame: Through study completion, an average of 90 ± 15 days post-stroke (will be assessed on 90 Day FU visit )

  2. Change in Montreal Cognitive Assessment (global cognitive function)

    Tertiary/Exploratory: To show that the BQ therapy is effective in reducing cognitive impairment at 3 months post-stroke, when initiated 4 to 14 days following an ischemic stroke.

    Time frame: will be assessed at 90 Day FU visit

  3. Change in Patient Health Questionnaire-8 (depression)

    Tertiary/Exploratory: To show that the BQ therapy is effective in reducing depression at 3 months post-stroke, when initiated 4 to 14 days following an ischemic stroke.

    Time frame: will be assessed on 90 Day FU visit

  4. Change in Academic Medical Center Linear Disability Scale (granular level of disability) at 90 days post-stroke.

    Tertiary/Exploratory: To show that the BQ therapy is effective in reducing fine-grained level of disability at 3 months post-stroke, when initiated 4 to 14 days following an ischemic stroke.

    Time frame: will be assessed on 90 Day FU visit

  5. Change from Baseline in Modified Rankin Scale (global disability)

    Tertiary/Exploratory: To characterize the long-term effect at 6 months post-stroke of the BQ therapy effect on upper limb functionality

    Time frame: change from baseline (4-21 days post-stroke) to 180 days post-stroke. will be assessed at 6 month FU visit

  6. Change from Baseline in Stroke Impact Scale Hand Domain (patient-reported hand function)

    Tertiary/Exploratory: To characterize the long-term effect at 6 months post-stroke of the BQ therapy effect on upper limb functionality

    Time frame: change from baseline (4-21 days post-stroke) to 180 days post-stroke will be assessed at 6 month FU visit

  7. Change from Baseline in 5-level EQ-5D (health-related quality of life) at 180 days post-stroke.

    Tertiary/Exploratory:To characterize the long-term effect at 6 months post-stroke of the BQ therapy effect on health-related quality of life (HRQoL).

    Time frame: change from baseline (4-21 days post-stroke) to 180 days post-stroke (will be assessed at 6 month FU visit )

  8. Formal cost-effectiveness analysis over a lifetime horizon from the perspective of the United States healthcare system.

    Tertiary/Exploratory: To formally evaluate the cost-effectiveness of the BQ therapy over a lifetime horizon from the perspective of the United States healthcare system.

    Time frame: Will be assessed at 90 day FU visit and 6 month FU visit

  9. adherence to treatment as measured by the Qompass

    To explore the relationship between adherence to treatment as measured by the Qompass

    Time frame: Will be assessed upon data base lock

07

Study locations

15 sites
  • Rancho Research Institute
    Downey, California 90242, United States
  • Ronald Reagan UCLA Medical Center & California Rehabilitation Institute
    Los Angeles, California 90095, United States
  • MedStar National Rehabililtaion Hospital,
    Washington, District of Columbia 20010, United States
  • Brooks Rehabilitation Hospital - University Campus
    Jacksonville, Florida 32216, United States
  • The Miami Project to Cure Paralysis
    Miami, Florida 33136, United States
  • Shirley Ryan Abilitylab
    Chicago, Illinois 60611, United States
  • KU Medical Center
    Kansas City, Kansas 66160, United States
  • Spaulding Rehabilitation Hospital
    Boston, Massachusetts 02129, United States
  • JFK Johnson Rehabilitation Institute
    Edison, New Jersey 08820, United States
  • Kessler Institute of Rehabilitation
    West Orange, New Jersey 07052, United States
  • NYP Brooklyn Methodist Hospital Outpatient Rehabilitation
    Brooklyn, New York 11215, United States
  • Atrium Health Carolinas Rehabilitation
    Charlotte, North Carolina 28203, United States
  • Moss Rehabilitation Research Institute
    Elkins Park, Pennsylvania 19027, United States
  • Baylor Scott & White Institute for Rehabilitation
    Dallas, Texas 75246, United States
  • TIRR Memorial Hermann Hospital
    Houston, Texas 77030, United States
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Nov 2023, 23 months.

Of 80 industry-sponsored interventional studies with no phase under Ischemic Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 46. This study's 23 months is close to that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2021
First posted
Sep 14, 2021
StartActual
Dec 4, 2021
Primary completionActual
Nov 6, 2023
CompletionActual
Jan 16, 2024
Last update
Mar 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05044507
Lead sponsor
BrainQ Technologies Ltd.
Responsible party
Sponsor
First posted
Sep 14, 2021
Start date
Dec 4, 2021
Primary completion
Nov 6, 2023
Completion
Jan 16, 2024
Last update
Mar 19, 2024

Study contacts

Jeffrey L Saver, MD
principal investigator · Lead Coordinating PI
Pamela W Duncan, PhD
principal investigator · Lead Coordinating PI

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion